Effects of spironolactone treatment on an experimental model of chronic aortic valve regurgitation

DC FieldValueLanguage
dc.contributor.authorZendaoui, Adnane-
dc.contributor.authorLachance, Dominic-
dc.contributor.authorRoussel, Élise-
dc.contributor.authorCouët, Jacques-
dc.contributor.authorArsenault, Marie-
dc.date.accessioned2017-11-14T18:14:51Z-
dc.date.available2017-11-14T18:14:51Z-
dc.date.issued2012-07-01-
dc.identifier.issn0966-8519fr
dc.identifier.urihttp://hdl.handle.net/20.500.11794/15827-
dc.description.abstractBACKGROUND AND AIM OF THE STUDY : Aortic regurgitation (AR) is a disease for which there is currently no effective medical treatment. It has been shown previously in an experimental model of AR that the renin-angiotensin-aldosterone system (RAAS) plays a major role, and that medications blocking the RAAS are effective to protect against left ventricular (LV) hypertrophy and also help to maintain a normal systolic function. The role of aldosterone receptor blockers in this disease has never been evaluated. Thus, the effects were studied of the aldosterone receptor blocking agent spironolactone in a model of chronic AR in rats. METHODS : The effects of a six-month treatment with spironolactone were evaluated in adult Wistar rats with severe AR, compared to sham-operated and untreated AR animals. RESULTS : Spironolactone treatment decreased the total heart weight. In addition, the LV expression of atrial natriuretic peptide mRNA was decreased by spironolactone treatment, as was the expression of collagen 1 and LOX1 mRNAs. Left ventricular fibrosis was decreased by spironolactone treatment. CONCLUSION : Spironolactone protected against volume-overload cardiomyopathy in this model of aortic valve regurgitation. The predominant protective effect was a decrease in myocardial fibrosis.fr
dc.languageengfr
dc.publisherICRfr
dc.subjectAortic valve regurgitationfr
dc.subjectVolume overloadfr
dc.subjectLeft ventricular hypertrophyfr
dc.subjectAldosterone receptor blockersfr
dc.titleEffects of spironolactone treatment on an experimental model of chronic aortic valve regurgitationfr
dc.title.alternativeSpironolactone treatment for aortic valve regurgitationfr
dc.typeCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherchefr
dcterms.bibliographicCitationThe Journal of heart valve disease, Vol. 21 (4), 478-486 (2012)fr
dc.identifier.pubmed22953675fr
dc.subject.rvmSpironolactone -- Effets physiologiquesfr
dc.subject.rvmCœur -- Ventricule gauche -- Hypertrophiefr
dc.subject.rvmCœur -- Valvules -- Maladiesfr
dc.subject.rvmAntialdostéronesfr
rioxxterms.versionAccepted Manuscriptfr
rioxxterms.project.funder_nameCanadian Institutes of Health Researchfr
rioxxterms.project.funder_nameQuebec Heart Institute Foundationfr
bul.rights.periodeEmbargo12 moisfr
Collection:Articles publiés dans des revues avec comité de lecture

Files in this item:
SizeFormat 
Zendaoui et al. JHVD.pdf234.32 kBAdobe PDFView/Open
All documents in CorpusUL are protected by Copyright Act of Canada.